Summary
EYEN Chart
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study
EYEN stock craters on the decision to terminate late-stage myopia study of MicroPine following negative feedback from an independent Data Review Committee.
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline
On Friday, Eyenovia, Inc. EYEN stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating its proprietary drug-device combination of low-dose atropine in the company's Optejet dispensing platform pediatric progressive myopia.
Eyenovia to discontinue late-stage study for eye drug
Eyenovia said on Friday it would terminate a late-stage study testing its experimental drug-device combination for pediatric progressive myopia as it failed to meet the main goal.
Hyperion DeFi, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SBI Samuel Bridgers, III Redwood Wealth Management Group LLC | 183,273 | $1.19M | $1.76M | $569,254.4 | 47.98% |
 Christopher C. Powers Farther Finance Advisors, LLC | 105 | $1,006 | $1,005.9 | -$0.1 | -0.01% |
| AFL Abound Financial LLC ABOUND FINANCIAL, LLC | 890 | $3,071 | $3,070.5 | -$0.5 | -0.02% |
| JH Julie Hazzard 10Elms LLP | 90 | $99 | $99 | - | - |
Hyperion DeFi, Inc. (EYEN) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Hyperion DeFi, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Michael M. Rowe CEO | NASDAQ (CM) Exchange | 30234E203 CUSIP |
| US Country | 13 Employees | - Last Dividend | 3 Feb 2025 Last Split | 25 Jan 2018 IPO Date |
Overview
Eyenovia, Inc. is an innovative ophthalmic technology company that focuses on crafting therapeutics equipped with its distinctive microdose array print platform technology. Based in New York, New York, Eyenovia has made significant strides since its inception in 2014, originally starting its journey as PGP Holdings V, Inc. before rebranding to its current identity in May 2014. The company has established itself in the field of eye care by developing solutions aimed at addressing common eye conditions such as myopia, presbyopia, and the need for pharmaceutical mydriasis. Through strategic licensing agreements, Eyenovia has expanded its potential market reach beyond the United States to include Canada, China, South Korea, and through partnerships with Bausch Health Ireland Limited, Arctic Vision (Hong Kong) Limited, and Senju Pharmaceutical Co., Ltd., showcasing its global ambitions.
Products and Services
- MicroPine
- MicroLine
- Mydcombi
MicroPine represents Eyenovia's foray into addressing pediatric myopia progression, a frequent concern regarding children's eye health. Currently in Phase III clinical development, MicroPine illustrates the company's commitment to halting the worsening of near-sightedness in the pediatric population. It showcases the potential of Eyenovia's microdose technology in providing a novel treatment method. The product's reach extends to the United States and Canada under a licensing agreement with Bausch Health Ireland Limited, and further to China and South Korea through a separate agreement with Arctic Vision (Hong Kong) Limited.
MicroLine is Eyenovia's answer to presbyopia, a condition associated with aging that impairs near vision. This product is also under Phase III clinical development, signaling its advanced stage towards achieving regulatory approval. MicroLine aims to improve the quality of life for those affected by presbyopia, providing a clinically tested solution based on Eyenovia's proprietary technology. Eyenovia has taken steps to ensure its commercialization in key markets through licensing agreements for regions such as China and South Korea with Arctic Vision (Hong Kong) Limited.
The Mydcombi product is under Phase III clinical development with a focus on providing a solution for pharmaceutical mydriasis, which is essential for various eye examinations and procedures. Mydcombi's development underscores Eyenovia's broader strategy to address a range of ophthalmic conditions using its microdose array print technology. With partnerships for its development and commercialization, including with Arctic Vision (Hong Kong) Limited for China and South Korea and Senju Pharmaceutical Co., Ltd., Eyenovia pushes the boundaries of traditional eye care practices.
